Baseline Serum Cholesterol Levels Predict the Response of Patients with Advanced Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitor-Based Treatment [Corrigendum]


The authors have advised due to an error at the time of figure assembly, Figure 2D on page 4048 is incorrect. The correct Figure 2 is shown as follows:

**Figure 2 Continued.**
The authors apologize for this error and advise it does not affect the results of the paper.

**Figure 2** Survival analysis of patients with hypercholesterolemia or hypocholesterolemia based on the ICI-based treatment.

**Notes:** PFS and OS comparison of patients with different level of serum cholesterol; (A) PFS in total population (n=169, mPFS:4.4m VS 7.9m, P<0.001); (B) OS in total population (n=169, mOS:8.0m VS 11.0m, P<0.001); (C) PFS in population of unknown/no/low PD-L1 expression (n=121, mPFS:3.7m VS 7.5m, P<0.001); (D) OS in population of unknown/no/low PD-L1 expression (n=121, mOS:7.2m VS 10.0m, P<0.001); (E) PFS in population of high PD-L1 expression (n=48, mPFS:4.9m VS 8.9m, P<0.001); (F) OS in population of PD-L1 expression (n=48, mOS:9.9m VS 13.9m, P<0.001). PFS, progression-free survival; OS, overall survival.